Shambhu Aryal, Shalika B Katugaha, Adam Cochrane, Anne Whitney Brown, Steven D Nathan, Oksana A Shlobin, Kareem Ahmad, Lauren Marinak, Jessica Chun, Margaret Fregoso, Shashank Desai, Christopher King
BACKGROUND: Cytomegalovirus (CMV) infection is common in thoracic organ transplant recipients. Valganciclovir and ganciclovir are used for both prophylaxis and treatment of this infection, but intolerance and treatment failure are common. Letermovir has been demonstrated to reduce the risk of CMV infection when used for prophylaxis in allogeneic hematopoietic cell transplantation. However, there are no data on its efficacy in thoracic organ transplantation. METHODS: We examined the use of letermovir for either CMV prophylaxis (primary and secondary) or treatment in heart and lung transplant recipients at our institution from February 1, 2018, through December 31, 2018...
December 2019: Transplant Infectious Disease: An Official Journal of the Transplantation Society